- Home
- PSTV vs CTXR Comparison
PSTV vs CTXR Comparison
Compare PSTV & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- CTXR
- Stock Information
- Founded
- PSTV 1996
- CTXR 2007
- Country
- PSTV United States
- CTXR United States
- Employees
- PSTV N/A
- CTXR N/A
- Industry
- PSTV Medical/Dental Instruments
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- CTXR Health Care
- Exchange
- PSTV Nasdaq
- CTXR Nasdaq
- Market Cap
- PSTV 17.0M
- CTXR 18.7M
- IPO Year
- PSTV N/A
- CTXR N/A
- Fundamental
- Price
- PSTV $0.70
- CTXR $1.25
- Analyst Decision
- PSTV Strong Buy
- CTXR Strong Buy
- Analyst Count
- PSTV 3
- CTXR 3
- Target Price
- PSTV $10.83
- CTXR $53.00
- AVG Volume (30 Days)
- PSTV 19.1M
- CTXR 484.1K
- Earning Date
- PSTV 08-22-2025
- CTXR 08-22-2025
- Dividend Yield
- PSTV N/A
- CTXR N/A
- EPS Growth
- PSTV N/A
- CTXR N/A
- EPS
- PSTV N/A
- CTXR N/A
- Revenue
- PSTV $5,206,000.00
- CTXR N/A
- Revenue This Year
- PSTV $8.26
- CTXR N/A
- Revenue Next Year
- PSTV $8.39
- CTXR $365.90
- P/E Ratio
- PSTV N/A
- CTXR N/A
- Revenue Growth
- PSTV N/A
- CTXR N/A
- 52 Week Low
- PSTV $0.16
- CTXR $0.65
- 52 Week High
- PSTV $2.31
- CTXR $20.00
- Technical
- Relative Strength Index (RSI)
- PSTV 60.91
- CTXR 41.95
- Support Level
- PSTV $0.45
- CTXR $1.21
- Resistance Level
- PSTV $0.90
- CTXR $1.43
- Average True Range (ATR)
- PSTV 0.12
- CTXR 0.11
- MACD
- PSTV 0.02
- CTXR -0.04
- Stochastic Oscillator
- PSTV 57.45
- CTXR 7.84
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.